相关实验视频
Updated: Jul 11, 2025

12:59
Barnes Maze Testing Strategies with Small and Large Rodent Models
Published on: February 26, 2014
42.0K
代谢障碍治疗方法及其对记忆的影响
Punita Aggarwal1, Faiz Khan1, Sugato Banerjee1
1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, India.
CNS & neurological disorders drug targets
|November 3, 2023
概括
代谢综合征,包括糖尿病,高血压和高胆固醇,影响大脑健康和记忆力. 本综述探讨了代谢综合征的常见治疗方法如何影响认知功能和记忆.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢综合征,以糖尿病,高血压和高脂血症等疾病为特征,显著影响认知功能并增加痴呆风险.
- 代谢障碍与神经健康 (尤其是记忆) 的相互作用是一个日益增长的研究领域.
- 现有的文献提出了关于代谢综合征治疗对认知的影响的相互矛盾的发现.
研究的目的:
- 在过去的三十年里,审查和总结了代谢综合征常用的药物和营养药对学习和记忆的影响.
- 研究抗糖尿病,低脂,抗高血压和高胆固醇药物的潜力,以减轻与代谢综合征相关的认知障碍.
- 探索这些治疗可能影响β-粉样蛋白积累和认知功能的机制.
主要方法:
- 对过去30年发表的研究进行了全面的文献综述.
- 对研究的分析,研究了抗糖尿病药物 (例如,甲福明,利拉古,达巴格利弗洛辛,胰岛素),低脂剂 (例如,纤维酸盐,他类药物),抗高血压药物 (例如,ACEI,CCB) 和营养药对记忆的影响.
- 审查研究探讨这些治疗对β-粉样蛋白积累的影响的研究.
主要成果:
- 一些抗糖尿病药物,如甲福明可以增强记忆力,而长期使用胰岛素可能导致记忆力下降.
- 一些抗高血压药物 (ACEI,CCB),低脂药物 (他类药物,纤维化药物) 和营养药物通过各种机制显示出改善认知的潜力.
- 关于代谢综合征治疗对β-粉样蛋白积累的影响的证据是矛盾的,一些研究表明减少,而另一些则反驳它.
结论:
- 代谢综合征的治疗方法对记忆和认知功能有着不同的,有时是相反的影响.
- 需要进一步的研究来澄清这些药物的长期神经后果,并确定最佳的治疗策略,以保持代谢综合征患者的认知健康.
- 了解这些影响对于制定预防或延迟受代谢障碍影响越来越多的人群认知衰退的干预措施至关重要.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
130
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
130
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Inborn Errors of Metabolism
166
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
166
Role of Neurotransmitters in Memory
583
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
583
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K

